

Clinical Guideline

Epilepsy and pregnancy management

Policy developed by: SA Maternal & Neonatal Clinical Network

Approved SA Health Safety & Quality Strategic Governance Committee on:

19 December 2014

Next review due: 31 December 2017

Summary Clinical practice guideline on Epilepsy and pregnancy management

Keywords Epilepsy and pregnancy management, neurological, seizures, antiepileptic, miscarriage, neural tube defects, orofacial defects, congenital, heart, hypospadias, congenital anomalies, hypertelorism, , newborn, vomiting, anticonvulsants, mirena, absence seizures, muscle contractions, rash, breastfed, breastfeeding, lamotrigine, confused, headache, bladder control, clinical guideline

Policy history Is this a new policy? **N**
Does this policy amend or update an existing policy? **Y**
Does this policy replace an existing policy? **Y**
If so, which policies? **Epilepsy and pregnancy management**

Applies to All SA Health Portfolio
All Department for Health and Ageing Divisions
All Health Networks
CALHN, SALHN, NALHN, CHSALHN, WCHN, SAAS

Staff impact All Staff, Management, Admin, Students, Volunteers
All Clinical, Medical, Nursing, Allied Health, Emergency, Dental, Mental Health, Pathology

PDS reference CG185

Version control and change history

Version	Date from	Date to	Amendment
1.0	27 April 04	15 Dec 08	Original version
2.0	15 Dec 08	08 Jan 13	Reviewed
3.0	08 Jan 13	09 Dec 14	Reviewed
4.0	19 Dec 14	Current	

South Australian Perinatal Practice Guidelines

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Note:

This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials.

The clinical material offered in this statewide standard/policy provides a minimum standard, but does not replace or remove clinical judgement or the professional care and duty necessary for each specific patient case. Where care deviates from that indicated in the statewide guideline contemporaneous documentation with explanation must be provided.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for:

- > Discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes the use of interpreter services where necessary,
- > Advising consumers of their choice and ensuring informed consent is obtained,
- > Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- > Documenting all care in accordance with mandatory and local requirements

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Table 1 - Classification of epileptic seizures according to clinical type

Partial (focal, local) seizures	
Simple partial seizures (SPS)	
Temporal lobe SPS are the most common type of SPS	Symptoms can include: <ul style="list-style-type: none"> > An 'epigastric rising sensation' > Dèjà vu (the feeling of 'having been here before') or jamais vu (where familiar things seem new) > A flashback of memory > A sudden, intense feeling of fear or joy > A funny taste or smell
Frontal lobe SPS can be harder to describe	Some people experience: <ul style="list-style-type: none"> > Strange movements > A feeling of a wave going through the head or body > Stiffness or jerking of part of the body that might start in one place, for example the face, and spread to other parts of the body
Parietal lobe SPS	Often include strange sensations such as: <ul style="list-style-type: none"> > Numbness or tingling > Burning sensations or a feeling of heat > A feeling that part of the body, an arm or leg, is bigger or smaller than they really are
Occipital lobe SPS	Involve visual sensations, such as: <ul style="list-style-type: none"> > Distortion or loss of vision > Seeing flashing lights or coloured shapes > Seeing people or objects that are not there (hallucinations)
Complex partial seizures (CPS)	
Temporal lobe CPS	Most common CPS <ul style="list-style-type: none"> > Automatism such as lip-smacking or chewing movements, or rubbing, stroking or fiddling with their hands; > Or looking from one side to another in a confused way
Frontal lobe CPS	Often much shorter than temporal lobe CPS, usually lasting about 15-30 seconds: <ul style="list-style-type: none"> > Make strange postures with their arms or legs; or > Make juddering movements

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Generalised seizures (convulsive or non convulsive)	
Tonic-clonic seizures	Tonic-clonic seizures involve a tonic phase, in which the muscles suddenly contract, causing the person to fall and lie rigid. Up to a minute later, the seizure enters the clonic phase, when the muscles begin to alternate between relaxation and rigidity. The person may lose bowel or bladder control. The seizure usually lasts for 2–3 minutes, after which the person remains unconscious for a while. On waking, the person is likely to have a headache and to be confused and tired
Clonic seizures	A series of myoclonic contractions that regularly recur at a rate of 0.2 – 5/second
Atonic seizures	Cause a loss of postural tone. The result is loss of posture (head drops, falls) and are often preceded by a short myoclonic seizure
Myoclonic seizures	Short muscle contractions, usually lasting < 400 milliseconds
Absence seizures	Impairment of consciousness alone or with: mild clonic, atonic or tonic components, automatisms and/or autoimmune symptoms or signs
Secondarily generalized seizures	
Partial seizures evolving to secondary generalized seizures (may be generalized tonic-clonic, tonic or clonic)	SPS evolving to generalized seizures
	CPS evolving to generalized seizures
	SPS evolving to CPS and then evolving to generalized seizures
Unclassified seizures	

Adapted from: International League against Epilepsy (ILEA) classification. Available from URL: <http://www.ilae.org/> and Luders H, Acharya J, Baumgartner C, Benbadis S, Bleasel A, Burgess R *et al.* Semiological seizure classification. *Epilepsia* 1998; **39**:1006-13.

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Epilepsy

- > Epilepsy is a common neurological condition characterised by seizures¹
- > Epileptic seizures are caused by paroxysmal discharges of excessive and / or hyper-synchronous abnormal activity of cerebral cortical neurones
- > Drug use to control epilepsy in the population ranges from 4 to 9 per 1,000²
- > Most women with epilepsy will need to continue taking antiepileptic drugs in pregnancy to prevent the harmful effects of seizures
- > The treatment goal in pregnancy is to maintain a balance between an effective but low dose of a single antiepileptic drug and the harmful effects of seizures³

Literature review

- > In Australia, approximately 1,500 to 2,000 women on antiepileptic drugs become pregnant per year
- > Retrospective studies report a 2- to 3-fold increase in adverse pregnancy outcomes for women on antiepileptic drugs. These include:
 - > Miscarriage
 - > Major congenital malformations (neural tube defects, orofacial defects, congenital heart abnormalities and hypospadias)
 - > Minor congenital anomalies (hypertelorism, epicanthic folds and digital hypoplasia)
 - > Microcephaly
 - > Intrauterine growth restriction⁷
- > Pregnant women with untreated epilepsy are not at increased risk of having a baby with a birth defect^{8,9}

Pre-pregnancy care

- > In order to enable informed decisions and choice, and to reduce misunderstandings, women with epilepsy and their partners, as appropriate, must be given accurate information and counselling about
 - > Contraception
 - > Conception
 - > Pregnancy
 - > Caring for their baby and breastfeeding

Contraception

- > Advise all women with epilepsy of childbearing age that the risk of failure of oral contraceptive agents is increased several-fold if they are taking an enzyme-inducing antiepileptic drug (e.g. phenobarbital, phenytoin, carbamazepine, or primidone)

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

South Australian Perinatal Practice Guidelines

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Conception

- > Pre-pregnancy counselling should provide a clear understanding of the risks of uncontrolled seizures and the possible teratogenicity of anticonvulsant agents
 - > For women taking sodium valproate pre-pregnancy, consideration should be given to a suitable alternative agent if appropriate
- > Most experts currently recommend high dose folic acid for women taking antiepileptic medication i.e. 5mg / day (10 times the prophylactic dose) for 1 month before conception and continue during the first trimester¹³
- > Genetic counselling is required if both parents have epilepsy or the disease is inherited
- > Aim for seizure control at least 6 months before conception and, if possible, cease or use the lowest effective dose of a single anticonvulsant according to the type of epilepsy
- > If anticonvulsant drugs are required aim to achieve levels in the therapeutic range before conception

Pregnancy

- > Arrange review by a neurologist or specialist physician
- > Obtain complete blood picture and serum folate levels
- > Explain the importance of continuing anticonvulsant medication when this is necessary because of the maternal and fetal risks associated with convulsions
- > Women should be re-assured that there is no evidence that simple partial, complex partial, absence and myoclonic seizures affect the pregnancy or developing fetus adversely unless they fall and sustain an injury

Antiepileptic drugs (AEDs)

- > In Australia, the following commonly used antiepileptic drugs have been available for 20 years:
 - > Carbamazepine (ADEC Cat D)
 - > Clonazepam (ADEC Cat C)
 - > Ethosuximide (ADEC Cat D)
 - > Phenobarbitone (ADEC Cat D)
 - > Phenytoin (ADEC Cat D)
 - > Primidone (ADEC Cat D)
 - > Sodium valproate (ADEC Cat D)
 - > Sulthiame (ADEC Cat D)

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

South Australian Perinatal Practice Guidelines

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

- > In recent years new antiepileptic drugs have been released
 - > Gabapentin (ADEC Cat B1)
 - > Lacosamide (ADEC Cat B3)
 - > Lamotrigine (ADEC Cat D)
 - > Levetiracetam (ADEC Cat B3)
 - > Oxcarbazepine (ADEC Cat D)
 - > Pregabalin (ADEC Cat B3)
 - > Tiagabine (ADEC Cat B3)
 - > Topiramate (ADEC Cat D)
 - > Vigabatrin (ADEC Cat D)
 - > Zonisamide (ADEC Cat D)
- > The following drugs are enzyme-inducing antiepileptic drugs
 - > Carbamazepine
 - > Oxcarbazepine
 - > Phenobarbitone
 - > Phenytoin
 - > Primidone
 - > Topiramate

Phenytoin

- > Narrow therapeutic window
- > Increased clearance rate during pregnancy, leading to decreased serum concentrations
- > Fall in total serum phenytoin concentrations may lead to poor seizure control
- > Consideration should be given to monitoring phenytoin levels¹⁴ (Harden et al. 2009)
- > Associated major malformations are facial clefts, congenital heart defects and urogenital defects
- > Associated with Fetal Hydantoin Syndrome (FHS) in 10 % of exposed fetuses (dysmorphic facies and other features, distal phalangeal hypoplasia, abnormal growth and mental / motor development)¹⁵

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Carbamazepine

- > Large peak-trough fluctuations can be minimised by using a controlled-release formulation¹⁰, but this may require higher doses
- > Pregnancy may cause a small decrease in the concentration of carbamazepine; consideration should be given to monitoring levels¹⁴
- > Associated with major malformations including neural tube defects in up to 1 % of exposed pregnancies, heart defects, inguinal hernia, hypospadias and hip dislocations
- > Craniofacial abnormalities and developmental delay have been associated in some but not all studies with the use of carbamazepine both alone or with other anticonvulsants¹⁵

Sodium valproate

- > Divided doses are preferred to avoid high peaks in serum concentrations
- > Therapeutic range not closely correlated with efficacy – drug level monitoring is of limited value apart from suspected toxicity or non-compliance
- > Exposure to valproate during early pregnancy is associated with a 1 to 2 % incidence of neural tube defects, especially with doses > 1,000 mg / day
- > Other defects include cardiovascular complications, urogenital malformations, skeletal defects; and facial dysmorphic patterns
- > Large studies have produced an estimate of the incidence of congenital malformations in children exposed to valproic acid during pregnancy ranging from 5 to 18 %¹⁵
- > Emerging evidence suggests that valproate exposure in pregnancy may lead to neurodevelopmental delay (including decreased mental development, intelligence quotient (IQ) and cognition, and autism spectrum disorder)¹⁵

Phenobarbital and Primidone

- > Barbiturates are now less frequently prescribed due to their tendency to produce sedation and impaired cognitive function
- > Associated with congenital heart defects and facial clefts
- > Infants born after exposure to phenobarbitone or primidone in utero should be monitored for withdrawal symptoms for up to 6 weeks after birth

Lamotrigine

- > Lamotrigine clearance may be increased in pregnancy, leading to a reduction in lamotrigine concentrations and potential loss of seizure control¹⁴
- > Lamotrigine levels should be monitored in pregnancy and the dose adjusted accordingly¹⁴
- > To date data suggest that lamotrigine has not been shown to increase the risk of major birth defects, however there are conflicting reports of an association with the increased risk of oral facial clefts¹⁵

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

South Australian Perinatal Practice Guidelines

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

New antiepileptic drugs

- > Gabapentin, lamotrigine, levetiracetam and vigabatrin have no antifolate effects¹⁰
- > To date there has been no evidence of an increased incidence of major malformations with most of the newer antiepileptic drugs, although data are limited^{7,16}
- > Topiramate has been changed From ADEC category B3 to category D after inconsistent reports of an increased risk in facial clefts¹⁵

Management

- > The management of seizure activity is covered in PPG, seizures in pregnancy

Antenatal

- > Physician / neurology review in each trimester
- > Document history of seizure activity
- > Maternal serum screening for alpha-fetoprotein at 14 – 20⁺⁶ weeks
- > Offer first trimester combined screening for aneuploidy with detailed early morphology
 - > Ensure the request form for obstetric ultrasound includes details of all antiepileptic drugs the woman is taking
- > Detailed ultrasound assessment of the fetus at 18 – 20 weeks gestation (looking particularly for heart, renal and neural tube defects)
 - > Ensure the request form for obstetric ultrasound includes details of all antiepileptic drugs the woman is taking
- > Monitor plasma anticonvulsant levels (not useful for valproate) every 1 to 2 months. If there is deterioration in seizure control, adjust dose accordingly
- > Women should be advised about the importance of proper sleep and medication compliance, particularly in the last trimester, when AED levels tend to be lowest
- > Women should be encouraged to participate in the Australian Pregnancy Register for Women on Antiepileptic Drugs: tel: 1800 069 722⁷

Vitamin K₁

- > Enzyme inducing antiepileptic drugs:
 - > Carbamazepine
 - > Oxcarbazepine
 - > Phenobarbitone
 - > Phenytoin
 - > Primidone
 - > Topiramate
- > are known to cross the placenta and promote oxidative degradation of vitamin K₁ in the fetus
- > Consider antenatal prophylaxis **with oral vitamin K₁ 20 mg per day in the last 4 weeks of pregnancy** if enzyme-inducing drugs are used (Konakion[®] MM ampoules 10 mg / 1 mL have Therapeutic Goods Administration [TGA] approval for oral use)

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

South Australian Perinatal Practice Guidelines

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

- > If vitamin K₁ has not been given antenatally, administer intravenous vitamin K₁ 10 mg by slow injection over 5 minutes in labour or threatened preterm labour

Intrapartum

- > Most women with epilepsy will have a normal uncomplicated vaginal birth
- > Two to four percent of women with epilepsy will have a tonic-clonic seizure during labour or in the first 24 hours after labour (see management in seizures in pregnancy)
- > Tonic clonic seizures may result in fetal hypoxia
- > Birth should be arranged in a hospital with facilities for emergency caesarean section and maternal and neonatal resuscitation
- > Continue oral anticonvulsants
- > Ensure intravenous access
- > Paediatrician / neonatologist at birth

NOTE: Phenytoin and phenobarbitone are the only parenteral antiepileptics

- > Women will not usually need parenteral anticonvulsants in labour unless they are vomiting and unable to take their usual anti-convulsant medication
- > Women who have missed their anticonvulsant doses for more than 12 hours may need a parenteral dose. Consult a physician or neurologist.
- > For women already on oral phenytoin, continue the same dose intravenously (divided doses)
- > If the woman is on a different anticonvulsant, she will require a phenytoin loading dose (15 – 20 mg / kg) followed by maintenance doses of 8 mg / kg / day, approximately 300 mg, twice daily intravenously or orally
- > Intravenous diazepam 5-10 mg can be used for acute seizure management in women on other anti-epileptic drugs (see management of seizures in pregnancy)

Immediately following birth

- > Advise the mother that intramuscular vitamin K₁ should be administered to the newborn immediately after birth, and is the preferred method
 - > 1 mg for term babies
 - > 0.5 mg for babies < 1.5 kg bodyweight
- > If vitamin K₁ is preferred by the mother to be given orally, administer 3 doses of 2
 - > Give first dose immediately following birth
 - > Second dose on day three to five
 - > Last dose at four weeks
- > Observe baby closely for signs of respiratory depression
- > Examine baby for signs of anticonvulsant and epilepsy-associated dysmorphism

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

South Australian Perinatal Practice Guidelines

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Postpartum

Antiepileptic drugs

- > Continue antiepileptic drugs
- > Antiepileptic serum levels quickly revert to pre-pregnancy levels. Lamotrigine levels may increase and the dose will most likely need to be reduced

Newborn care

- > Some antiepileptic drugs (e.g. phenobarbitone and primidone) can result in drug accumulation in the newborn
- > Observe baby for level of alertness and signs of excessive drowsiness (may need to review breastfeeding)
- > Valproate may be associated with jitteriness
- > If maternal seizure control is poor there may be a risk of injury to the infant

Breastfeeding

- > As antiepileptic drugs are excreted in breast milk only in low concentrations encourage breastfeeding
- > If the mother is using antiepileptic drugs that are associated with drowsiness, monitor the breastfed baby for prolonged sedation, disinterest in feeding and inadequate weight gain, and ensure the mother is informed of safe sleeping practices
- > **Lamotrigine requires caution** –If a rash occurs in the baby, breastfeeding should be ceased and the cause of the rash urgently established.
- > For further information regarding antiepileptic drugs in breastfeeding contact the WCHN Medicines and Drug Information Centre – 08 8161 7222 Mon- Fri

Contraception

- > The oral progestogen-only pill or progesterone implant (Implanon[®]) is unreliable contraception for women on the enzyme-inducing anticonvulsants
 - > Carbamazepine
 - > Oxcarbazepine
 - > Phenobarbitone
 - > Phenytoin
 - > Primidone
 - > Topiramate
- > but acceptable for women on the others with the exception of lamotrigine
- > Lamotrigine: Combined oral contraceptives may increase lamotrigine's metabolism, decreasing its concentration and efficacy (during the week when inactive combined oral contraceptive sugar pill is taken lamotrigine's concentration may rise); consider using an alternative contraceptive; contact one of the [pregnancy drug information centres](#) (AMH)

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

- > Medroxyprogesterone acetate depot injection can be used and most guidance suggests shortening the usual 12 weeks interval to 10 weeks for women taking enzyme-inducing AEDs
- > Levonorgestrel IUD (Mirena) is also a useful contraceptive in these circumstances
- > Sequential pills or combined pills containing less than 50 micrograms of oestrogen may be associated with an increased incidence of breakthrough bleeding, or contraceptive failure, and should be avoided
- > Women taking enzyme-inducing AEDs and the combined oral contraceptive should be advised:
 - > To take at least 50 micrograms of ethinyloestradiol (e.g. Microgynon 50) and to report any breakthrough bleeding. If breakthrough bleeding occurs the dose of ethinyloestradiol can be increased to 80 – 100 micrograms

Discharge counselling

- > Offer advice to women at risk of further seizure activity to minimise any injury risk to baby:
 - > Feed baby seated low or on floor
 - > Bath baby with another person present whenever possible
 - > Minimise carrying of baby
 - > Use a pram with an automatic brake

Follow up

- > Arrange neurological or general practitioner follow up before discharge

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

References

1. Tatum IV WO, Liporace J, Benbadis SR, Kaplan PW. Archives of Internal Medicine 2004; 164: 137 – 146.
2. Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052 922 and age-specific fertility rates of women with epilepsy (Levell III-2).
3. Kaaja E, Kaaja R, Matila R, Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology 2002; 58: 549 – 553 (Level III-I).
4. Stokes T, Shaw EJ, Juarez-Garcia A, Camosso-Stefinovic J, Baker R. Clinical Guidelines and Evidence Review for the Epilepsies: diagnosis and management in adults and children in primary and secondary care 2004. London: Royal College of General Practitioners. Available from URL: <http://www.nice.org.uk/nicemedia/pdf/CG020fullguideline.pdf>
5. Luders H, Acharya J, Baumgartner C, Benbadis S, Bleasel A, Burgess R et al. Semiological seizure classification. Epilepsia 1998; 39:1006-13.
6. National Institute for Clinical Excellence (NICE). Newer drugs for epilepsy in adults. Technology appraisal guidance 76. National Institute for Clinical Excellence; March 2004. Available from URL: <http://www.nice.org.uk/nicemedia/pdf/TA076fullguidance.pdf>
7. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J of Clin Neuroscience 2003; 10: 543 – 549 (Level III-2).
8. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344: 1132 – 1138 (Level III-2).
9. Motherisk. Summer 2002; 15: 1. Available from URL: <http://www.motherisk.org/updates/Summer2002.php3>
10. Nulman I, Laslo D, Koren G. Treatment of epilepsy in pregnancy. Drugs 1999; 57: 535 – 544.
11. Morrow JI, Craig JJ. Anti-epileptic drugs in pregnancy: current safety and other issues. Expert opinion. Pharmacotherapy 2003; 4: 445 – 455.
12. Sabers A, Dam M, a-Rogvi-Hansen B, Boas J, Sidenius P, Laue FM, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109: 9 – 13.
13. Cote A-M, Opatrny L, Keyes R, Nulman I, Magee L. The practicalities fo managing seizures in pregnancy: A review. Fetal and Maternal Medicine Review 2004; 15 (2): 181-204
14. Harden C, Pennell P, Koppel B et al. Practice Parameter update: Management issues for women with epilepsy – Focus on pregnancy (an evidence-based review): Vitamin K, folic acid, blood levels and breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009; 73; 142-149
15. REPROTOX – Micromedex® Thomson Reuters (Healthcare) Inc. Vol 154, exp 12/2012
16. Molgaard-Nielsen D, Hvid A. Newer-Generation Antiepileptic Drugs and the Risk of Major Birth Defects, JAMA. 2011, 305 (19); 1996-2002
17. Luders H, Acharya J, Baumgartner C, Benbadis S, Bleasel A, Burgess R et al. Semiological seizure classification. Epilepsia 1998; 39:1006-13.

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cwwhs.perinatalprotocol@health.sa.gov.au

Epilepsy and pregnancy management

© Department of Health, Government of South Australia. All rights reserved.

Useful web sites

The Australian Pregnancy Register of Antiepileptic Drugs for Women in Pregnancy with Epilepsy and Allied Conditions

http://www.epilepsy-society.org.au/pages/documents/APR_info.pdf

International League against Epilepsy (ILEA). Available from URL: <http://www.ilae.org/>

Abbreviations

ADEC	Australian Drug Evaluation Committee
AEDs	Anti epileptic drugs
AMH	Australian Medicines Handbook
Cat	Category
CPS	Complex partial seizures
CYWHS	Children youth and Women's Health Service
e.g.	For example
Et al.	And others
FHS	Fetal Hydantoin Syndrome
IQ	Intelligence Quotient
IUD	Intrauterine device
Kg	Kilograms(s)
Mg	Milligram(s)
SPS	Simple partial seizures
TGA	Therapeutic Goods Administration
WCHN	Women's and Children's Hospital Network

Version control and change history

PDS reference: OCE use only

Version	Date from	Date to	Amendment
1.0	22 June 04	06 July 09	Original version
2.0	06 July 09	23 Nov 10	Reviewed
3.0	23 Nov 10	29 Nov 10	Reviewed
4.0	29 Nov 10	20 Nov 12	Reviewed
5.0	20 Nov 12	9 Dec 14	Reviewed
6.0	19 Dec 14	Current	Reviewed

ISBN number:
Endorsed by:
Contact:

978-1-74243-067-6
SA Maternal & Neonatal Clinical Network
South Australian Perinatal Practice Guidelines workgroup at:
cywhs.perinatalprotocol@health.sa.gov.au